The age-related vision dysfunction market reached a value of USD 64.7 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 86.7 Million by 2035, exhibiting a growth rate (CAGR) of 2.68% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 64.7 Million |
Market Forecast in 2035
|
USD 86.7 Million |
Market Growth Rate (2025-2035)
|
2.68% |
The age-related vision dysfunction market has been comprehensively analyzed in IMARC's new report titled "Age-Related Vision Dysfunction Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Age-related vision dysfunction refers to a range of visual impairments that commonly manifest as people grow older. It is a natural part of the aging process and can impact various aspects of visual function. The common symptoms often include diminished visual acuity, decreased ability to focus on close objects (presbyopia), reduced contrast sensitivity, and increased susceptibility to glare and night vision difficulties. These issues can significantly affect daily activities, such as reading, driving, and recognizing faces. Diagnosis of the ailment involves comprehensive eye examinations conducted by qualified optometrists or ophthalmologists. These investigations assess factors like visual acuity, refraction, and the health of the eye's internal structures, including the lens and retina. Tonometry may also be performed to measure intraocular pressure, helping to detect glaucoma, a condition often associated with aging eyes. Additionally, specialized tests might be conducted to evaluate contrast sensitivity and visual field, which can provide a thorough understanding of the patient's visual capabilities.
The expanding geriatric population, who are susceptible to retinal detachment, in which the gel-like vitreous inside the eye may shrink and pull away from the retina, leading to floaters and flashes, is primarily driving the age-related vision dysfunction market. In addition to this, the inflating utilization of potent medications, such as antioxidants, anti-VEGF injections, anti-inflammatory agents, etc., to control disease progression and mitigate symptoms is also creating a positive outlook for the market. Moreover, the widespread adoption of corrective surgical interventions, including cataract removal and lens replacement surgeries, is further bolstering the market growth. Apart from this, the rising usage of rehabilitative visual therapies, as they aid in maximizing the remaining vision, enhancing visual adaptation, and facilitating better daily living skills, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which emphasizes introducing or modifying genetic material in cells to rectify or replace the deteriorating genes linked to vision loss, is also augmenting the market growth. Furthermore, the escalating demand for innovative technologies, such as retinal implants and artificial vision systems, since they hold the potential to restore partial vision in patients with severe visual impairments, is expected to drive the age-related vision dysfunction market during the forecast period.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current age-related vision dysfunction marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Lucentis (Ranibizumab) | Genentech USA, Inc. |
Vabysmo (Faricimab) | Genentech USA, Inc. |
Vuity (Pilocarpine Hydrochloride Ophthalmic Solution) | AbbVie Inc. |
Beovu (Brolucizumab) | Novartis AG |
Tarcocimab tedromer | KODIAK SCIENCES INC. |
Surabgene Lomparvovec (ABBV-RGX-314) | REGENXBIO/AbbVie Inc. |
Risuteganib (Alg-1001) | Allegro Ophthalmics LLC |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Age-Related Vision Dysfunction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies